Open AccessProfiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience
Author(s) -
Simon Pape,
Frederik Nevens,
Chris Verslype,
Caroline Mertens,
Joost P.H. Drenth,
Eric T. Tjwa
Publication year - 2020
Publication title -
european journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 102
eISSN - 1473-5687
pISSN - 0954-691X
DOI - 10.1097/meg.0000000000001580
Subject(s) - medicine , azathioprine , calcineurin , autoimmune hepatitis , tacrolimus , adverse effect , maintenance therapy , hepatitis , surgery , transplantation , chemotherapy , disease
Therapy for autoimmune hepatitis (AIH) consists of steroid induction therapy, followed by maintenance therapy with azathioprine. However, up to 20% of patients experience either insufficient response or intolerance on first-line therapy. Calcineurin inhibitors (CNIs) are frequently used when first-line therapy fails. Although a number of studies report on efficacy, less is known on the patient trajectory before switch to CNIs. Our aim was to describe the road toward CNI therapy in AIH patients.